Health Law Advisor

JANUARY 13, 2022

The proposed decision, which is subject to public comments that are due to CMS by February 10, 2022, does not endorse nationwide Medicare coverage for these drugs. After the FDA approval, several large medical centers stated that they would not be administering Aduhelm due to concerns about its efficacy. [1]. What Happens Next?

Medicare 52

Medicare Medicare FDA Medicaid 52

HIT Consultant

OCTOBER 14, 2021

COVID was a wakeup call: state public health departments were unable to process test results quickly because of lack of a standard way for labs to report test results, slowing the pandemic response. So, high quality, accurate data will be an imperative for member satisfaction. via a mobile app.

COVID-19 98

COVID-19 FDA Medicare Medicare 98

Healthcare Law Blog

NOVEMBER 13, 2023

On November 6, 2023, the Centers for Medicare and Medicaid Services (“CMS”) released the contract year 2025 proposed rule for Medicare Advantage (“MA”) organizations and Part D sponsors (the “Proposed Rule”). The UM committee was established in April 2023 in the 2024 Medicare Advantage and Part D Final Rule (CMS-4201-F).

Medicare 59

Medicare Medicare Medicaid Medicaid 59

Hall Render

FEBRUARY 16, 2024

CALIFORNIA 8 ASCs opening in Florida, California and New York A bankrupt California hospital left a health care desert. CALIFORNIA 8 ASCs opening in Florida, California and New York A bankrupt California hospital left a health care desert. The health system’s prices are already high.

US Department of Health and Human Services 40

US Department of Health and Human Services Nursing Homes Nurses Hospitals 40

Health Law Advisor

JULY 21, 2023

On June 22, 2023, the Centers for Medicare & Medicaid Services (CMS) announced its proposed “Transitional Coverage for Technologies” (TCET) pathway—the Biden administration’s highly anticipated take on a mechanism to expedite coverage for certain devices designated by the U.S.

FDA 52

FDA Medicare Medicare Patient Advocacy 52